Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VALN
stocks logo

VALN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.840
sliders
Low
13.00
Averages
15.00
High
18.00
Current: 8.840
sliders
Low
13.00
Averages
15.00
High
18.00
Guggenheim
Buy
downgrade
$14 -> $13
2025-09-08
Reason
Guggenheim
Price Target
$14 -> $13
2025-09-08
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.
Jefferies
Maury Raycroft
Buy
downgrade
$18 -> $14
2025-08-25
Reason
Jefferies
Maury Raycroft
Price Target
$18 -> $14
2025-08-25
downgrade
Buy
Reason
Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.
H.C. Wainwright
Brandon Folkes
Buy
maintain
$18
2025-08-25
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$18
2025-08-25
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes reiterates a Buy rating on Valneva after the FDA suspended the license for Ixchiq following four new reports of serious adverse events consistent with chikungunya-like illness. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025, the analyst tells investors in a research note. The firm points out that management noted Ixchiq represents a relatively small portion of its near-term revenue expectations. The stock selloff today offers an attractive entry for investors who are constructive on a potential positive readout for VLA15 later this year, contends H.C. Wainwright. It views the selloff as overdone and keeps an $18 price target on Valneva.
H.C. Wainwright
Brandon Folkes
initiated
$18
2025-08-19
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$18
2025-08-19
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Valneva with a Buy rating and $18 price target. The firm says Valneva is a commercial-stage vaccine company with a "strong proprietary portfolio." VLA15 offers a "de-risked, relatively high-probability path" to potential blockbuster sales, the analyst tells investors in a research note.
Guggenheim
Vamil Divan
Buy
downgrade
$15 -> $14
2025-05-08
Reason
Guggenheim
Vamil Divan
Price Target
$15 -> $14
2025-05-08
downgrade
Buy
Reason
Guggenheim analyst Vamil Divan lowered the firm's price target on Valneva to $14 from $15 and keeps a Buy rating on the shares. Valneva released detailed Q1 results and provided a corporate update, then announced that the European Medicines Agency is temporarily suspending the use of Valneva's chikungunya vaccine Ixchiq in people over 65 years old as part of the ongoing review of serious adverse events, notes the firm, which is modestly lowering its Ixchiq revenue estimates to account for this new potential safety concern.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2025-04-15
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2025-04-15
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is -8.11, compared to its 5-year average forward P/E of -226.64. For a more detailed relative valuation and DCF analysis to assess Valneva SE 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-226.64
Current PE
-8.11
Overvalued PE
461.43
Undervalued PE
-914.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.53
Current EV/EBITDA
-20.69
Overvalued EV/EBITDA
54.18
Undervalued EV/EBITDA
-55.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.93
Current PS
3.34
Overvalued PS
5.70
Undervalued PS
2.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VALN News & Events

Events Timeline

(ET)
2025-08-25
06:53:04
Valneva reveals U.S. FDA has suspended IXCHIQ's license.
select
2025-07-29 (ET)
2025-07-29
10:31:41
Valneva signs development, manufacturing agreement with AGC Biologics
select
2025-06-09 (ET)
2025-06-09
09:27:09
UK restricts use of Valneva chikungunya vaccine for safety review
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-28Yahoo Finance
Valneva reduces R&D operations by closing its French facility

  • Valneva's Facility Closure: Valneva is shutting down its Nantes facility, which handles operational and R&D activities, to consolidate its operations in Lyon, resulting in the termination of 30 positions.

  • Impact of FDA Suspension: The company faced a significant setback when the FDA suspended the license for its chikungunya vaccine, Ixchiq, due to safety concerns, leading to a downgrade in its 2025 sales forecast.

  • Ongoing Research and Development: Despite the facility closure, Valneva will not discontinue any R&D work, as research will be centralized at its Vienna site, where most of the R&D is already conducted.

  • Future Vaccine Developments: Valneva announced positive Phase II results for its Lyme disease vaccine candidate, developed with Pfizer, with plans for regulatory submissions in 2026 pending successful Phase III data.

[object Object]
Preview
9.0
11-27Benzinga
Valneva Reports Encouraging Results for Lyme Vaccine Booster as Pfizer Aims for 2026 Regulatory Submissions

  • VLA15 Vaccine Study Results: Valneva SE reported strong immunogenicity and safety data from its Phase 2 study of the Lyme disease vaccine candidate VLA15, showing a robust immune response and favorable safety profile six months after a third booster dose.

  • Collaboration with Pfizer: Valneva's collaboration with Pfizer, initiated in April 2020, aims to develop and commercialize VLA15, with plans for Pfizer to submit regulatory applications in 2026, pending positive Phase 3 data.

  • Dosing Schedule Findings: The study confirmed that a three-dose primary vaccination schedule resulted in higher antibody levels compared to a two-dose schedule, particularly in children aged 5 to 11, supporting the use of yearly booster doses.

  • Organizational Changes: Valneva announced a strategic initiative to optimize its operations in France by consolidating its activities in Lyon and closing its Nantes site to enhance operational effectiveness for long-term success.

[object Object]
Preview
4.5
11-27Newsfilter
Valneva Concentrates French Operations in Lyon to Enhance Efficiency
  • Strategic Consolidation: Valneva announced the concentration of its French operations in Lyon, closing the Nantes site, which aims to enhance overall efficiency through operational and R&D integration, thereby laying a foundation for the company's long-term success.
  • R&D Centralization: All R&D activities will be relocated to Vienna, ensuring efficient resource utilization and strengthening the company's competitiveness in vaccine development, especially in the context of an increasingly competitive global vaccine market.
  • Employee Support: Valneva is committed to providing support to affected employees during the transition, ensuring a smooth process that not only helps maintain employee morale but also enhances the company's reputation in the industry.
  • Vaccine Hub: Lyon, recognized as an international vaccine hub with major players, will further solidify Valneva's strategic position in vaccine R&D, promoting future business growth opportunities.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Valneva SE (VALN) stock price today?

The current price of VALN is 8.84 USD — it has increased 2.2 % in the last trading day.

arrow icon

What is Valneva SE (VALN)'s business?

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

arrow icon

What is the price predicton of VALN Stock?

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Valneva SE (VALN)'s revenue for the last quarter?

Valneva SE revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?

Valneva SE. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Valneva SE (VALN)'s fundamentals?

The market is revising Downward the revenue expectations for Valneva SE (VALN) for FY2025, with the revenue forecasts being adjusted by -7.29% over the past three months. During the same period, the stock price has changed by 2.20%.
arrow icon

How many employees does Valneva SE (VALN). have?

Valneva SE (VALN) has 676 emplpoyees as of December 05 2025.

arrow icon

What is Valneva SE (VALN) market cap?

Today VALN has the market capitalization of 756.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free